Carter T. Fields

2.3k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Carter T. Fields is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carter T. Fields has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carter T. Fields's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Inflammatory Bowel Disease (3 papers). Carter T. Fields is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Inflammatory Bowel Disease (3 papers). Carter T. Fields collaborates with scholars based in United States, United Kingdom and Switzerland. Carter T. Fields's co-authors include Gail D. Lewis Phillips, Mark X. Sliwkowski, Kathryn L. Parsons, Deepak Sampath, Teemu T. Junttila, Robert W. Akita, Lori S. Friedman, Steven R. Brant, Theodore M. Bayless and Michael Pickles and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and Cancer Cell.

In The Last Decade

Carter T. Fields

17 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

2009 651 citations Teemu T. Junttila, Robert W. Akita et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carter T. Fields United States	9	811	517	483	403	257	17	1.4k
George R. Gunn United States	11	475 0.6×	379 0.7×	432 0.9×	193 0.5×	547 2.1×	21	1.3k
Randall J. Brezski United States	23	551 0.7×	963 1.9×	769 1.6×	132 0.3×	917 3.6×	32	2.0k
Mark Egan United Kingdom	17	372 0.5×	207 0.4×	701 1.5×	157 0.4×	175 0.7×	27	1.4k
Diana F. Hausman United States	18	584 0.7×	142 0.3×	538 1.1×	203 0.5×	472 1.8×	40	1.6k
Andries C. Bloem Netherlands	23	628 0.8×	185 0.4×	706 1.5×	113 0.3×	709 2.8×	57	1.9k
Gustav Ullenhag Sweden	24	1.1k 1.4×	149 0.3×	633 1.3×	291 0.7×	837 3.3×	97	1.8k
Brian Cao United States	17	381 0.5×	135 0.3×	638 1.3×	168 0.4×	92 0.4×	37	1.2k
Khaled Tolba United States	17	493 0.6×	214 0.4×	632 1.3×	129 0.3×	464 1.8×	50	1.5k
Fiorella Petronzelli Italy	18	252 0.3×	200 0.4×	480 1.0×	177 0.4×	391 1.5×	41	1.2k
T C Meeker United States	22	986 1.2×	396 0.8×	822 1.7×	216 0.5×	619 2.4×	29	2.3k

Countries citing papers authored by Carter T. Fields

Since Specialization

Citations

This map shows the geographic impact of Carter T. Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carter T. Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carter T. Fields more than expected).

Fields of papers citing papers by Carter T. Fields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carter T. Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carter T. Fields. The network helps show where Carter T. Fields may publish in the future.

Co-authorship network of co-authors of Carter T. Fields

This figure shows the co-authorship network connecting the top 25 collaborators of Carter T. Fields. A scholar is included among the top collaborators of Carter T. Fields based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carter T. Fields. Carter T. Fields is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Brémovà-Ertl, Tatiana, William Evans, Carter T. Fields, et al.. (2023). N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study. Trials. 24(1). 361–361. 13 indexed citations

Phillips, Gail D. Lewis, Guangmin Li, Jun Guo, et al.. (2016). Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates. Cancer Research. 76(14_Supplement). 1207–1207. 4 indexed citations

Junttila, Melissa R., Weiguang Mao, Xi Wang, et al.. (2015). Targeting LGR5 ⁺ cells with an antibody-drug conjugate for the treatment of colon cancer. Science Translational Medicine. 7(314). 314ra186–314ra186. 127 indexed citations

Phillips, Gail D. Lewis, Carter T. Fields, Guangmin Li, et al.. (2013). Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clinical Cancer Research. 20(2). 456–468. 148 indexed citations

Crocker, Lisa, Carter T. Fields, Lily Shao, et al.. (2012). Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo. Cancer Research. 72(8_Supplement). 1212–1212. 2 indexed citations

Junttila, Teemu T., Robert W. Akita, Kathryn Parsons, et al.. (2011). Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell. 20(6). 818–818. 16 indexed citations

Fields, Carter T., et al.. (2010). Abstract S3-6: Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo. Cancer Research. 70(24_Supplement). S3–6. 5 indexed citations

Parsons, Kathryn L., et al.. (2010). 86 Potent anti-tumor activity of T-DM1 antibody–drug conjugate in combination with chemotherapeutic agents in breast tumor cells. European Journal of Cancer Supplements. 8(7). 35–35. 2 indexed citations

Fields, Carter T., et al.. (2010). 223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance. European Journal of Cancer Supplements. 8(7). 73–73. 10 indexed citations

10.

Fields, Carter T., Lisa Crocker, Mark X. Sliwkowski, & Gail D. Lewis Phillips. (2010). Abstract 5607: Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab. Cancer Research. 70(8_Supplement). 5607–5607. 5 indexed citations

11.

Fields, Carter T., Guangmin Li, Wei Wei Prior, et al.. (2009). Abstract #3239: Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase. Cancer Research. 69. 3239–3239. 3 indexed citations

12.

Junttila, Teemu T., Robert W. Akita, Kathryn L. Parsons, et al.. (2009). Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell. 15(5). 429–440. 651 indexed citations breakdown →

13.

Junttila, Teemu T., Carter T. Fields, Lisa Crocker, et al.. (2008). 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel. European Journal of Cancer Supplements. 6(12). 163–163. 5 indexed citations

14.

Fields, Carter T., et al.. (2006). Pharmacokinetics of a novel closantel/ivermectin injection in cattle. Journal of Veterinary Pharmacology and Therapeutics. 29(3). 205–211. 23 indexed citations

15.

Brant, Steven R., Carter T. Fields, Romulo Baltazar, et al.. (1998). American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology. 115(5). 1056–1061. 116 indexed citations

16.

Cho, Judy H., Dan L. Nicolae, Carter T. Fields, et al.. (1998). Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1. Proceedings of the National Academy of Sciences. 95(13). 7502–7507. 312 indexed citations

17.

Brant, Steven R., Dan L. Nicolae, Michele C. LaBuda, et al.. (1998). A genome wide screen of Crohn's disease in a large pedigree shows evidence for linkages to chromosomes 11, 16, 8 and 15. Gastroenterology. 114. A941–A941. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact